CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
SOHO 前沿更新与后续问题 | CAR-T 细胞治疗与双特异性抗体在套细胞淋巴瘤中的现状
英文原题：SOHO State of the Art Updates and Next Questions | The Current State of CAR T-Cell Therapy and Bispecific Antibodies in Mantle Cell Lymphoma.
查看英文原题
SOHO State of the Art Updates and Next Questions | The Current State of CAR T-Cell Therapy and Bispecific Antibodies in Mantle Cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
布鲁顿酪氨酸激酶（BTK）抑制剂治疗后复发的套细胞淋巴瘤（MCL）患者预后较差，该病仍不可治愈。双特异性抗体（BsAb）和CAR-T 细胞疗法是治疗复发/难治性MCL的新策略。在这一既往疗效不佳的领域中，这些疗法显示出良好结局和副作用特征。本综述详细介绍BsAb和CAR-T 细胞疗法治疗复发/难治性MCL的现有数据，以及当前治疗模式如何调整以纳入这些新型药物。
展开英文摘要原文
MCL remains incurable, and patients who relapse post BTK inhibitors have poor outcomes. BsAbs and CAR T cell therapy are novel strategies to treat patients with R/R MCL. These therapies exhibit favorable outcomes and side effect profiles in a previously dismal space. This review looks to detail the current data available for BsAbs and CAR T cell therapy in R/R MCL, and how are current treatment paradigm is shifting to incorporate these novel agents.
论文信息
- 作者
- Weiss JM、Phillips TJ
- 第一作者单位
- Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI.United States
- 通讯作者单位
- Department of Hematology and Hematopoietic Cell Transplantation, Division of Lymphoma, City of Hope Comprehensive Cancer Center, Duarte, CA. Electronic address: tphillips@coh.org.United States
- 文献类型
- 综述
- 期刊
- Clinical lymphoma, myeloma & leukemia2025 May
- 原文标识
- PubMed 39523133 · DOI 10.1016/j.clml.2024.10.009